The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
 
Bach Ardalan
No Relationships to Disclose
 
Aaron Ciner
Employment - Bristol-Myers Squibb/Celgene
 
Yasmine Baca
Employment - Caris Life Sciences
 
Sourat Darabi
Honoraria - OncoLens
Consulting or Advisory Role - Bayer; BostonGene
 
Anup Kasi
Consulting or Advisory Role - Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Jose Ignacio Azqueta
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Anthony F. Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Andrew Aguirre
Stock and Other Ownership Interests - Riva Therapeutics
Honoraria - Phillips Gilmore Oncology
Consulting or Advisory Role - Alcon (I); Arrakis Therapeutics; AstraZeneca; Boehringer Ingelheim; Merck; Mirati Therapeutics; Nimbus Therapeutics; Plexium; Revolution Medicines; Riva Therapeutics; SERVIER; Syros Pharmaceuticals; T-Knife
Research Funding - Bristol-Myers Squibb/Celgene; Deerfield Management; Mirati Therapeutics; Novartis; Novo Ventures; Revolution Medicines; Syros Pharmaceuticals
 
Harshabad Singh
Research Funding - AstraZeneca/Daiichi Sankyo
(OPTIONAL) Uncompensated Relationships - Natera; Seagen
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Exelixis; Genentech; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Immunovaccine; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; IDEAYA Biosciences; Merck; Merus; Novartis; Pfizer; Pionyr; Seagen; TriSalus Life Sciences
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); RenovoRx (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - Amgen; Merck
Research Funding - BeiGene (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); PharmaMar (Inst); Takeda (Inst); TLC PharmaChem (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364